Lunai Bioworks Inc. (RENB) Financials
Newest figures come from the 10-Q for Q3 FY2026, filed May 15, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RENB SEC filings page.
This page shows Lunai Bioworks Inc. (RENB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Lunai Bioworks has no reported revenue, persistent cash outflows, and a balance sheet that shifted from positive equity to a deficit.
Total assets fell from$163.1M in FY2024 to$8.2M in FY2025, while liabilities remained roughly unchanged. That combination turned equity from$132.0M positive to-$21.3M , making the balance-sheet contraction more consequential than the annual cash outflow alone.
Operating cash flow was negative in every reported year, moderating from
Short-term liquidity remained severely mismatched: the current ratio stayed below 0.1x in both FY2024 and FY2025, meaning current liabilities greatly exceeded current assets. With negative equity in FY2025, the pressure reflects both immediate obligations and a weakened overall capital base.
Financial Health Signals
Lunai Bioworks Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Lunai Bioworks Inc. generated $21K in revenue in Q3 2026.
Lunai Bioworks Inc.'s EBITDA was -$1.5M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 64.5% from the same quarter a year earlier. Against the prior quarter it is up 19.1%.
Lunai Bioworks Inc. reported -$2.6M in net income in Q3 2026. This represents a decrease of 1459.3% from the same quarter a year earlier. Against the prior quarter it is down 42.9%.
Lunai Bioworks Inc. earned -$0.10 per diluted share (EPS) in Q3 2026. Against the prior quarter it is down 25.0%.
Cash & Balance Sheet
Lunai Bioworks Inc. recorded an outflow of $1.0M in free cash flow in Q3 2026, representing a cash shortfall after capex.
Lunai Bioworks Inc. held $3.2M in cash as of Q3 2026; long-term debt is not reported for that period.
Not reported for Q3 2026.
Margins & Returns
Lunai Bioworks Inc.'s gross margin was 100.0% in Q3 2026, indicating the percentage of revenue retained after direct costs.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q3 2026.
Capital Allocation
Lunai Bioworks Inc. invested $16K in research and development in Q3 2026. Against the prior quarter it is down 65.2%.
Not reported for Q3 2026.
RENB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $21K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $21K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $16K | $46K-71.5% | $24K-93.7% | N/A | N/A | $161K-74.0% | $390K-31.1% | N/A |
| SG&A Expenses | $1.4M-66.4% | $1.8M-59.4% | $2.4M-54.5% | N/A | $4.2M-44.8% | $4.4M+20.4% | $5.3M-36.1% | N/A |
| Operating Income | -$1.5M+64.5% | -$1.8M+59.9% | -$3.3M+93.8% | N/A | -$4.2M+91.9% | -$4.5M-6.5% | -$53.3M-500.4% | N/A |
| EBITDA | -$1.5M+64.5% | -$1.8M+59.9% | -$3.3M+93.9% | N/A | -$4.1M+92.0% | -$4.5M-6.5% | -$53.3M-501.9% | N/A |
| Interest Expense | $108K-42.7% | $122K+22.9% | $122K-51.1% | N/A | $189K-37.9% | $99K-64.0% | $250K+39.5% | N/A |
| Net Income | -$2.6M-1459.3% | -$1.8M+75.2% | $2.8M+106.4% | N/A | $189K+100.3% | -$7.3M-60.1% | -$44.2M-381.9% | N/A |
| EPS (Basic) | -$0.10 | -$0.08+82.2% | $0.13+104.7% | N/A | $0.00+100.0% | -$0.45-542.9% | -$2.76-1871.4% | N/A |
| EPS (Diluted) | -$0.10 | -$0.08 | $0.13+104.7% | N/A | $0.00+100.0% | -$0.45 | -$2.76 | N/A |
| Diluted Shares (Avg) | 25M | 23M | 23M+40.8% | N/A | 16M-85.0% | 16M | 16M | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Income Tax.
RENB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $9.9M-91.6% | $6.7M-94.0% | $7.0M-94.3% | $8.2M-95.0% | $117.7M-33.9% | $111.3M+91.9% | $121.8M+111.7% | $163.1M+179.8% |
| Current Assets | $3.7M+1.8% | $514K-69.9% | $800K-58.9% | $1.0M-47.6% | $3.7M+200.7% | $1.7M-28.9% | $1.9M+2.2% | $2.0M-22.1% |
| Cash & Equivalents | $3.2M+241.8% | $492K+57.7% | $625K+183.3% | $93K-58.0% | $923K+195.2% | $312K+27.8% | $221K-57.9% | $220K-88.2% |
| Accounts Receivable | N/A | N/A | N/A | N/A | $964K | N/A | N/A | N/A |
| Goodwill | $6.0M-94.7% | $6.0M-94.5% | $6.0M-95.0% | $6.0M-96.3% | $112.6M-31.4% | $108.0M+827.8% | $118.2M+915.2% | $159.3M+1268.8% |
| Total Liabilities | $19.4M-33.8% | $20.2M-31.0% | $20.0M-15.8% | $29.6M-5.0% | $29.3M-32.8% | $29.3M+103.0% | $23.7M+119.5% | $31.2M+164.0% |
| Current Liabilities | $19.3M-33.1% | $20.0M-30.1% | $19.7M-14.4% | $29.2M-3.8% | $28.8M+38.2% | $28.6M+107.9% | $23.0M+128.2% | $30.3M+175.0% |
| Non-Current Liabilities | $131K-73.6% | $214K-68.3% | $279K-60.7% | $425K-49.6% | $498K-97.8% | $674K+1.5% | $710K-1.5% | $842K+8.6% |
| Total Equity | -$9.6M-110.8% | -$13.5M-116.5% | -$13.0M-113.3% | -$21.3M-116.2% | $88.4M-34.2% | $82.1M+88.2% | $98.1M+109.8% | $132.0M+183.8% |
| Retained Earnings | -$512.0M-33.4% | -$509.4M-32.7% | -$507.6M-34.8% | -$510.5M-53.5% | -$383.7M-21.2% | -$383.9M-49.0% | -$376.7M-48.8% | -$332.5M-36.2% |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Long-Term Debt.
RENB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.0M+31.0% | -$1.1M+58.2% | -$1.3M+33.1% | -$1.8M+25.0% | -$1.5M+43.5% | -$2.6M+18.7% | -$2.0M+27.4% | -$2.4M-6.7% |
| Depreciation & Amortization | $11K-65.6% | $11K-64.7% | $42K+28.2% | N/A | $32K+5.5% | $32K-3.2% | $32K+18.8% | N/A |
| Stock-Based Compensation | $169K-88.7% | $129K-76.9% | $181K-49.3% | N/A | $1.5M-19.5% | $559K-44.1% | $358K-63.6% | N/A |
| Capital Expenditures | $0 | N/A | N/A | N/A | N/A | N/A | N/A | $24K+283.5% |
| Free Cash Flow | -$1.0M | N/A | N/A | N/A | N/A | N/A | N/A | -$2.4M-7.5% |
| Investing Cash Flow | $0 | -$1K | $545K | $964K+1906.9% | N/A | N/A | $0+100.0% | -$53K-769.1% |
| Financing Cash Flow | $3.7M+3.3% | $950K-63.3% | $1.3M-33.8% | $178K-92.8% | $3.6M+35.7% | $2.6M-9.0% | $2.0M-20.8% | $2.5M+97.6% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
RENB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -7054.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -12278.6% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | 0.2%+44.1pp | -8.8%+1.6pp | -45.1%-25.4pp | N/A |
| Return on Assets | -26.1%-26.2pp | -27.0%-20.5pp | 40.5%+76.8pp | N/A | 0.2%+33.3pp | -6.5%+1.3pp | -36.3%-20.4pp | N/A |
| Current Ratio | 0.19+0.1x | 0.030.0x | 0.040.0x | 0.040.0x | 0.13+0.1x | 0.06-0.1x | 0.08-0.1x | 0.07-0.2x |
| Debt-to-Equity | N/A | N/A | N/A | N/A | 0.330.0x | 0.360.0x | 0.240.0x | 0.240.0x |
| Asset Turnover | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Margin | -4903.3% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$21.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.04), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Lunai Bioworks Inc. RENB | FY2025 | N/A | N/A | N/A | $46.3M | — |
| Radiopharm Theranostics Limited RADX | FY2025 | $3.6M | -$38.3M | N/A | $16.5M | 20/100 |
| Tempest Therapeutics, Inc. TPST | FY2025 | N/A | -$26.3M | N/A | $12.8M | — |
| Acrivon Therapeutics, Inc. ACRV | FY2025 | N/A | -$77.9M | N/A | $81.8M | — |
| Barinthus Biotherapeutics plc American BRNS | FY2025 | $0 | -$66.4M | N/A | $30.2M | — |
| BIOATLA INC BCAB | FY2025 | N/A | $59.6M | N/A | $2.9M | — |
Where Lunai Bioworks Inc. Ranks
Frequently Asked Questions
What is Lunai Bioworks Inc.'s operating cash flow?
Lunai Bioworks Inc. (RENB) recorded an outflow of $7.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Lunai Bioworks Inc.'s total assets?
Lunai Bioworks Inc. (RENB) had $8.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Lunai Bioworks Inc. spend on research and development?
Lunai Bioworks Inc. (RENB) invested $537K in research and development during fiscal year 2025.
What is Lunai Bioworks Inc.'s current ratio?
Lunai Bioworks Inc. (RENB) had a current ratio of 0.04 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Why is Lunai Bioworks Inc.'s debt-to-equity ratio negative or not reported?
Lunai Bioworks Inc. (RENB) has negative shareholder equity of -$21.3M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.